Latest Market Share News

Karoon Energy plans to expand its on-market share buyback program by an additional US$75 million, aiming to invest a total of US$125 million in shares by the end of 2025 amid a belief that its stock is undervalued.

Mach7 Technologies has initiated a A$5 million on-market share buy-back program, reflecting confidence in its robust financial health and growth outlook. The move underscores the company’s commitment to capital management amid reaffirmed FY25 revenue growth guidance.

BlueBet Holdings has delivered positive EBITDA for the first half of FY25 ahead of schedule, driven by strategic customer reactivation and enhanced platform efficiencies following its merger with betr.

Acrux Limited has launched its Nitroglycerin 0.4% Ointment and successfully raised nearly $4 million, positioning the specialty pharma company for sustained revenue growth.

Carnarvon Energy has announced a strategic on-market buy-back of up to 10% of its shares, signaling confidence despite the recent deferral of its Dorado Development Project.

Mitchell Services reported a $46.7 million revenue and $5.6 million EBITDA in Q2 FY25, reflecting a strategic transition phase marked by increased mobilisation for new projects in PNG and decarbonisation drilling. Despite short-term softness, the company’s strengthened balance sheet and expanded service offerings position it for growth.

Bioxyne Limited has reported a remarkable 77% jump in revenue for Q2 FY2025, alongside positive operating cash flow, as it prepares to expand manufacturing capacity and enter new international markets.

Myer Holdings has completed its strategic acquisition of Just Group, adding five key apparel brands to its portfolio and issuing 890.5 million new shares to Premier Investments.

Bioxyne Limited reports a remarkable 77% revenue increase in Q2 FY2025 alongside positive operating cash flow, setting the stage for international growth with upcoming UK export approvals and a planned European GMP facility.

Coventry Group reports a slight dip in H1 FY25 sales but manages a modest EBITDA increase, buoyed by a successful ERP upgrade and strategic growth initiatives.

Bioxyne Limited has raised its FY2025 revenue forecast to $25 million, driven by a remarkable 267% increase in first-half revenue and strong momentum from its subsidiary Breathe Life Sciences.

Praemium has reported a record 29% increase in total Australian funds under administration (FUA) to $62.1 billion in Q2 FY2025, driven by strong net inflows and the successful launch of its next-generation IDPS, Spectrum.